v3.25.1
Interim Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 464 $ 713
Accounts and notes receivable, net 858 770
Inventories 1,550 1,463
Prepaid expenses and other 61 71
Total current assets 2,933 3,017
Property, plant, and equipment 9,624 9,572
Less: Accumulated depreciation (6,493) (6,389)
Property, plant, and equipment, net 3,131 3,183
Operating lease right-of-use assets 286 258
Goodwill 46 46
Other intangible assets, net 2 3
Investments in affiliates 164 152
Restricted cash and restricted cash equivalents 50 50
Other assets 782 804
Total assets 7,394 7,513
Current liabilities:    
Accounts payable 1,006 1,156
Compensation and other employee-related cost 123 99
Short-term and current maturities of long-term debt 43 54
Current environmental remediation 100 115
Other accrued liabilities 401 393
Total current liabilities 1,673 1,817
Long-term debt, net 4,064 4,054
Operating lease liabilities 213 194
Long-term environmental remediation 467 456
Deferred income taxes 28 35
Other liabilities 369 369
Total liabilities 6,814 6,925
Commitments and contingent liabilities
Equity    
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 198,438,218 shares issued and 149,568,021 shares outstanding at March 31, 2025; 198,300,033 shares issued and 149,428,431 shares outstanding at December 31, 2024) 2 2
Treasury stock, at cost (48,870,197 shares at March 31, 2025 and 48,871,602 at December 31, 2024) (1,804) (1,804)
Additional paid-in capital 1,060 1,055
Retained earnings 1,659 1,701
Accumulated other comprehensive loss (338) (367)
Total Chemours stockholders’ equity 579 587
Non-controlling interests 1 1
Total equity 580 588
Total liabilities and equity $ 7,394 $ 7,513